EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR) is a common driver gene in NSCLC, and approximately 20% of patients harbor activating EGFR mutations, making them targets for EGFR Tyrosine Kinase Inhibitors (EGFR-TKIs) (John et al., 2022; Roskoski, 2019).